What is Micron Biomedical?
Micron Biomedical specializes in the development of dissolving microneedle-based vaccine and drug delivery technology. Originally incubated within the laboratory of Dr. Mark Prausnitz at Georgia Tech, the company has evolved into a leader in non-invasive medical administration. Its core technology utilizes microscopic structures to deliver active pharmaceutical ingredients directly into the skin, offering a superior alternative to conventional hypodermic needles. This approach not only enhances patient compliance but also facilitates the distribution of vaccines in resource-limited settings, a mission supported by organizations such as the Bill & Melinda Gates Foundation and the CDC. The company operates at the intersection of biotechnology and pharmaceutical engineering, providing a platform that is increasingly vital for global health security and chronic disease management.
How much funding has Micron Biomedical raised?
Micron Biomedical has raised a total of $17M across 1 funding round:
Series A
$17M
Series A (2023): $17M with participation from J2 Ventures, Global Health Investment Fund, and LTS Lohmann Therapie-Systeme
Key Investors in Micron Biomedical
J2 Ventures
J2 Ventures is a venture capital firm that focuses on early-stage investments, providing strategic support to companies operating within the technology and healthcare sectors.
Global Health Investment Fund
A nonprofit organization dedicated to catalyzing the development of technologies that enhance human health globally, with a specific focus on vaccines, diagnostics, and therapeutics.
LTS Lohmann Therapie-Systeme
A pharmaceutical technology company specializing in the development and manufacturing of advanced drug delivery systems, including transdermal patches and microarray patch technologies.
What's next for Micron Biomedical?
With the recent capital infusion, Micron Biomedical is poised to scale its manufacturing capabilities and expand its clinical pipeline. The strategic focus will likely center on deepening partnerships with global pharmaceutical entities and public health organizations to bring its microneedle platforms to market. As the company moves beyond its initial development phase, the emphasis will shift toward regulatory milestones and the commercialization of its vaccine delivery systems. By maintaining its commitment to innovation and leveraging its robust network of institutional investors, Micron Biomedical is well-positioned to disrupt the traditional drug delivery market and address critical gaps in global healthcare accessibility.
See full Micron Biomedical company page
